Bristol-Myers Squibb fourth quarter 2013 revenues increase 6 percent to $4.

Bristol-Myers Squibb fourth quarter 2013 revenues increase 6 percent to $4.4 billion Bristol-Myers Squibb Business today reported results for the fourth one fourth and full 12 months of 2013 online pharmacy . The fourth one fourth was highlighted by the firm's announcement to sell its diabetes business within the continued development of its successful BioPharma strategy to a specialty care model. The ongoing company achieved important regulatory milestones in the quarter for Eliquis in the U.S., daclatasvir/asunaprevir in Japan, daclatasvir in Farxiga and Europe in the U.S. In addition, the business provided financial assistance for 2014. ‘In the fourth quarter we continuing to grow and evolve our business, delivering solid financial outcomes and attaining regulatory milestones for products that are important to our long-term achievement,’ said Lamberto Andreotti, ceo, Bristol-Myers Squibb.